Exactech (NASDAQ:EXAC) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, December 1st.
EXAC has been the subject of several other research reports. Robert W. Baird set a $34.00 target price on shares of Exactech and gave the company a “buy” rating in a report on Sunday, October 15th. Zacks Investment Research downgraded shares of Exactech from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Gabelli lowered shares of Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Sidoti lowered shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Exactech has an average rating of “Hold” and a consensus price target of $49.00.
Exactech (NASDAQ:EXAC) traded down $0.05 on Friday, reaching $50.25. 385,800 shares of the company’s stock traded hands, compared to its average volume of 72,761. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 4.08. Exactech has a 1 year low of $23.30 and a 1 year high of $50.95. The firm has a market capitalization of $724.99, a P/E ratio of 41.57, a price-to-earnings-growth ratio of 4.05 and a beta of 1.02.
Exactech (NASDAQ:EXAC) last released its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.03). The business had revenue of $61.40 million for the quarter, compared to analyst estimates of $61.78 million. Exactech had a return on equity of 7.22% and a net margin of 0.18%. analysts forecast that Exactech will post 1.29 earnings per share for the current year.
Large investors have recently modified their holdings of the business. Bank of Montreal Can bought a new position in Exactech during the second quarter worth about $134,000. Highbridge Capital Management LLC bought a new position in Exactech during the third quarter worth about $201,000. AMP Capital Investors Ltd bought a new position in Exactech during the third quarter worth about $215,000. Hancock Holding Co. bought a new position in Exactech during the second quarter worth about $212,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Exactech by 2,693.8% in the first quarter. JPMorgan Chase & Co. now owns 7,627 shares of the medical equipment provider’s stock valued at $192,000 after acquiring an additional 7,354 shares during the period. Hedge funds and other institutional investors own 66.30% of the company’s stock.
WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/12/exactech-exac-rating-lowered-to-hold-at-valuengine.html.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.